LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

107.35 0.3

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

105.47

Max

109.99

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+21.9% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.6B

14B

Ankstesnė atidarymo kaina

107.05

Ankstesnė uždarymo kaina

107.35

Naujienos nuotaikos

By Acuity

50%

50%

165 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-18 22:31; UTC

Uždarbis

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

2026-02-18 22:18; UTC

Uždarbis

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

2026-02-18 22:11; UTC

Uždarbis

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

2026-02-18 21:52; UTC

Uždarbis

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

2026-02-18 23:56; UTC

Rinkos pokalbiai

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

2026-02-18 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-18 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

2026-02-18 23:34; UTC

Rinkos pokalbiai
Uždarbis

Brambles' Cost Control Stands Out to Bull -- Market Talk

2026-02-18 23:33; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

2026-02-18 23:32; UTC

Rinkos pokalbiai

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

2026-02-18 22:45; UTC

Uždarbis

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

2026-02-18 22:44; UTC

Rinkos pokalbiai

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

2026-02-18 22:37; UTC

Uždarbis

Nutrien 4Q EPS $1.18 >NTR.T

2026-02-18 22:37; UTC

Uždarbis

Nutrien 4Q Sales $5.34B >NTR.T

2026-02-18 22:35; UTC

Uždarbis

Pan American Silver 4Q EPS $1.07 >PAAS

2026-02-18 22:35; UTC

Uždarbis

Pan American Silver 4Q Rev $1.18B >PAAS

2026-02-18 22:30; UTC

Uždarbis

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

2026-02-18 22:29; UTC

Uždarbis

Kinross Gold 4Q EPS 75c >K.T

2026-02-18 22:22; UTC

Uždarbis

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

2026-02-18 22:22; UTC

Rinkos pokalbiai

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

2026-02-18 22:16; UTC

Uždarbis

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

2026-02-18 22:05; UTC

Uždarbis

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

2026-02-18 22:03; UTC

Uždarbis

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q Sales $929M >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q EPS $1.68 >KALU

2026-02-18 22:00; UTC

Uždarbis

Kinross Gold 4Q Adj EPS 67c >KGC

2026-02-18 22:00; UTC

Uždarbis

Kinross Gold 4Q Sales $2.02B >KGC

2026-02-18 21:56; UTC

Uždarbis

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

2026-02-18 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

21.9% į viršų

12 mėnesių prognozė

Vidutinis 127.81 USD  21.9%

Aukščiausias 175 USD

Žemiausias 105 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

19

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

165 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat